Epidiolex Helps Control Seizures in Children Without Affecting Cognition, Study Reports

Epidiolex Helps Control Seizures in Children Without Affecting Cognition, Study Reports
0
(0)

Epidiolex, a cannabidiol add-on medication for treatment-resistant epilepsy, was safely given to children and teenagers for one year in a clinical trial that included youth with Lennox-Gastaut syndrome, a study reported. 

Seizure control was improved with no adverse treatment effects on cognition or functioning after one year, its researchers reported, adding there were also no significant changes in patients’ thinking abilities or functional status.

The study, “Cognitive function and adaptive skills after a one-year trial of cannabidiol (CBD) in a pediatric sample with treatment-resistant epilepsy,” was published in the journal Epilepsy & Behavior

Epidiolex, by GW Pharmaceuticals, is an oral cannabidiol approved to treat seizures in Lennox-Gastaut and Dravet syndrome patients ages 1 and older

Clinical trials have found that Epidiolex to be safe and well-tolerated, with reported side effects that include sleepiness, decreased appetite, diarrhea, and fatigue. (Cannabidiol is a non-psychoactive extract from marijuana, meaning it does not have the characteristic “high” associated with marijuana use.)

With any new anti-epileptic therapy, a complete analysis of adverse events as well as benefits beyond seizure control is essential. 

Studies investigating Epidiolex’s effects on cognition in adults with treatment-resistant epilepsy (TRE) — those whose seizures fail to respond to first-line medications or surgery  — have also shown long-term use to be well tolerated. 

However, “the potential [adverse events] or benefits of [Epidiolex] involving cognitive function have not been determined in pediatric populations with TRE,” the scientists wrote. 

Researchers at Children’s of Alabama, along with colleagues at the University of Alabama at Birmingham, looked at cognitive and functional effects of Epidiolex use for one year in children and teenagers with TRE.

They enrolled patients between the ages of 3 and 19 in a pediatric arm of an open-label Phase 1 study (NCT02700412 for adults; NCT02695537 is listed for children) assessing the safety and tolerability of Epidiolex as an add-on medication.

TRE was defined as a failure to respond to four or more anti-seizure therapies, including at least one attempt at using two of these medications concurrently. 

During the first visit (baseline visit), participants underwent physical, neurological, and laboratory testing. Treatment began with a daily dose of Epidiolex 5mg/kg, divided between the morning and evening, which was increased in 5 mg/kg increments over two weeks until a tolerable and effective dose was reached. The maximum dose was set at 50 mg/kg per day. 

Seizure severity was assessed using the Chalfont Seizure Severity Scale (CSSS) questionnaire, along with seizure calendars completed by caregivers. 

Cognitive skills were measured using the NIH Toolbox (NIHTB-CB), which includes seven tasks assessing attention, working memory, executive function, episodic memory, and language. 

Many of these patients had cognitive problems that left them unable to complete the toolbox, and their caregivers completed the Adaptive Behavior Assessment System (ABAS-II), which measures the ability to perform various daily life skills. 

Of the 87 children enrolled, 38 completed the cognitive or functional assessment given after one year of treatment. Of these, 14 were able to finish at least part of the NIHTB-CB questionnaire, while the other 24 were assessed using the ABAS-II.

No significant changes in cognitive performance or functional status after a yearlong stable dose of Epidiolex was seen in an analysis. 

There was a trend indicating better performance in one cognitive subdomain of the NIHTB-CB questionnaire: the Flanker Inhibitory Control and Attention Test, which measures response inhibition and attention.

An improvement was also seen in one functional subdomain of the ABAS-II: the social domain, which measures the ability to engage in leisure and social activities.

A significant decrease in seizure severity, as measured by the CSSS questionnaire, was reported after the year of treatment, but a correlation analysis found no relationship between cognitive or functional status and seizure severity scores.

Likewise, the last Epidiolex dose had little or no association with changes in cognitive performance or overall functional status. 

“Our findings suggest that [Epidiolex], as an add-on drug for the treatment of TRE in a pediatric sample, does not appear to cause [adverse effects] involving cognition or adaptive functioning in participants who completed one year of treatment,” the researchers wrote. 

“The current findings indicate that improved seizure control can be obtained without adversely affecting cognitive or adaptive functioning,” they added, recommending further study of “cognitive performance in PWE [people with epilepsy] who are participating in randomized placebo-controlled trials.”

Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.
Total Posts: 0
Ana de Barros, PhD Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.
×
Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.
Latest Posts
  • Epidiolex study
  • gene therapy
  • LGS mutation, mouse model
  • mutations

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published. Required fields are marked *